Taro Kishi1, Yuki Matsuda2,3, Nakao Iwata2. 1. Department of Psychiatry, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan. tarok@fujita-hu.ac.jp. 2. Department of Psychiatry, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan. 3. Department of Psychiatry, National Center Hospital of Neurology and Psychiatry, Kodaira, Tokyo, 187-8551, Japan.
Abstract
RATIONALE: We examined whether memantine add-on to antipsychotic treatment is beneficial in schizophrenia treatment. OBJECTIVE: This systematic review and meta-analysis aimed to achieve stronger evidence on the efficacy and safety of memantine add-on for treating schizophrenia. METHODS: We analyzed double-blind, randomized, placebo-controlled trials of memantine add-on treatment in schizophrenia patients receiving antipsychotics. The primary outcomes were amelioration of negative symptoms and all-cause discontinuation. Dichotomous outcomes are presented as risk ratios (RRs), and continuous outcomes are presented as mean differences (MDs) or standardized mean differences (SMDs). RESULTS: Eight studies (n = 448) were included. Although memantine add-on treatment was superior to placebo for ameliorating negative symptoms (SMD = -0.96, p = 0.006, I 2 = 88%; N = 7, n = 367) in the Positive and Negative Syndrome Scale general subscale (MD = -1.62, p = 0.002, I 2 = 0%; N = 4, n = 151) and Mini-Mental Status Examination score (MD = -3.07, p < 0.0001, I 2 = 21%; N = 3, n = 83), there were no statistically significant differences in the amelioration of overall (SMD = -0.75, p = 0.06, I 2 = 86%; N = 5, n = 271), positive (SMD = -0.46, p = 0.07, I 2 = 80%; N = 7, n = 367), and depressive symptoms (SMD = -0.127, p = 0.326, I 2 = 0%; N = 4, n = 201); all-cause discontinuation (RR = 1.34, p = 0.31, I 2 = 0%; N = 8, n = 448); and individual adverse events (fatigue, dizziness, headache, nausea, constipation) between the groups. For negative symptoms, the significant heterogeneity disappeared when risperidone studies alone were considered (I 2 = 0%). However, memantine add-on treatment remained superior to placebo (SMD = -1.29, p = 0.00001). Meta-regression analysis showed that patient age was associated with memantine-associated amelioration of negative symptoms (slope = 0.171, p = 0.0206). CONCLUSIONS: Memantine add-on treatment may be beneficial for treating psychopathological symptoms (especially negative symptoms) in schizophrenia patients. The negative-symptom effect size may be associated with younger adult schizophrenia patients.
RATIONALE: We examined whether memantine add-on to antipsychotic treatment is beneficial in schizophrenia treatment. OBJECTIVE: This systematic review and meta-analysis aimed to achieve stronger evidence on the efficacy and safety of memantine add-on for treating schizophrenia. METHODS: We analyzed double-blind, randomized, placebo-controlled trials of memantine add-on treatment in schizophreniapatients receiving antipsychotics. The primary outcomes were amelioration of negative symptoms and all-cause discontinuation. Dichotomous outcomes are presented as risk ratios (RRs), and continuous outcomes are presented as mean differences (MDs) or standardized mean differences (SMDs). RESULTS: Eight studies (n = 448) were included. Although memantine add-on treatment was superior to placebo for ameliorating negative symptoms (SMD = -0.96, p = 0.006, I 2 = 88%; N = 7, n = 367) in the Positive and Negative Syndrome Scale general subscale (MD = -1.62, p = 0.002, I 2 = 0%; N = 4, n = 151) and Mini-Mental Status Examination score (MD = -3.07, p < 0.0001, I 2 = 21%; N = 3, n = 83), there were no statistically significant differences in the amelioration of overall (SMD = -0.75, p = 0.06, I 2 = 86%; N = 5, n = 271), positive (SMD = -0.46, p = 0.07, I 2 = 80%; N = 7, n = 367), and depressive symptoms (SMD = -0.127, p = 0.326, I 2 = 0%; N = 4, n = 201); all-cause discontinuation (RR = 1.34, p = 0.31, I 2 = 0%; N = 8, n = 448); and individual adverse events (fatigue, dizziness, headache, nausea, constipation) between the groups. For negative symptoms, the significant heterogeneity disappeared when risperidone studies alone were considered (I 2 = 0%). However, memantine add-on treatment remained superior to placebo (SMD = -1.29, p = 0.00001). Meta-regression analysis showed that patient age was associated with memantine-associated amelioration of negative symptoms (slope = 0.171, p = 0.0206). CONCLUSIONS:Memantine add-on treatment may be beneficial for treating psychopathological symptoms (especially negative symptoms) in schizophreniapatients. The negative-symptom effect size may be associated with younger adult schizophreniapatients.
Authors: Daniel Kondziella; Eiliv Brenner; Elvar M Eyjolfsson; Katarina Ryden Markinhuhta; Maria L Carlsson; Ursula Sonnewald Journal: Neuropsychopharmacology Date: 2005-12-14 Impact factor: 7.853
Authors: Ahmad Fakhri; Sirous Pakseresht; Mohammad Reza Haghdoost; Nasihat Hekmatkhah; Maria Torkashvand; Behnam Ghorbanzadeh Journal: Acta Med Iran Date: 2016-11
Authors: Anna Höflich; Andreas Hahn; Martin Küblböck; Georg S Kranz; Thomas Vanicek; Christian Windischberger; Alois Saria; Siegfried Kasper; Dietmar Winkler; Rupert Lanzenberger Journal: Int J Neuropsychopharmacol Date: 2015-04-19 Impact factor: 5.176
Authors: William C Hochberger; Yash B Joshi; Michael L Thomas; Wendy Zhang; Andrew W Bismark; Emily B H Treichler; Melissa Tarasenko; John Nungaray; Joyce Sprock; Lauren Cardoso; Neal Swerdlow; Gregory A Light Journal: Neuropsychopharmacology Date: 2018-10-30 Impact factor: 7.853
Authors: Michael Y Bai; David B Lovejoy; Gilles J Guillemin; Rouba Kozak; Trevor W Stone; Maju Mathew Koola Journal: Complex Psychiatry Date: 2021-02-08
Authors: Neal R Swerdlow; Savita G Bhakta; Jo Talledo; Juliana Kotz; Benjamin Z Roberts; Royce Ellen Clifford; Michael L Thomas; Yash B Joshi; Juan L Molina; Gregory A Light Journal: Neuropsychopharmacology Date: 2020-09-22 Impact factor: 7.853